Hilary Coon | Medicine and Dentistry | Research Excellence Award

Published on by Invention Awards

Research Excellence Award

Hilary Coon
University of Utah School of Medicine

Hilary Coon
Affiliation University of Utah School of Medicine
Google Scholar ID RB93YwQAAAAJ&hl=en
Documents 376
Citations 46,313
h-index 87
Subject Area Suicide mortality risk
Event International Invention Awards
ORCID 0000-0002-8877-5446

Hilary Coon’s research profile is associated with the University of Utah School of Medicine and emphasizes genetic, epidemiological, and population-based approaches to suicide mortality risk. University materials describe her work as addressing genetic and environmental factors associated with complex psychiatric conditions, with research focused on risks leading to suicide mortality. [1]

Abstract

Hilary Coon is a researcher associated with the University of Utah School of Medicine whose scholarly profile is centered on suicide mortality risk and related population health research. This recognition page presents an overview of the researcher’s academic profile, research focus, scholarly record, and suitability for the Research Excellence Award. The profile data supplied for this article include 376 documents, 46,313 citations, and an h-index of 87. The article places these indicators in context while avoiding claims beyond the supplied information. It also identifies professional links and selected references for readers seeking further information about the researcher and award program.

Keywords

Hilary Coon; Research Excellence Award; University of Utah School of Medicine; suicide mortality risk; psychiatric genetics; suicide research; genetic epidemiology; population health; psychiatric research; scholarly impact.

Introduction

Hilary Coon’s research profile is associated with the University of Utah School of Medicine and emphasizes genetic, epidemiological, and population-based approaches to suicide mortality risk. University materials describe her work as addressing genetic and environmental factors associated with complex psychiatric conditions, with research focused on risks leading to suicide mortality. [1]

Research Profile

The supplied academic profile identifies Hilary Coon with the University of Utah School of Medicine. Her stated subject area is suicide mortality risk. University information also lists research interests spanning psychiatry, epidemiology, biomedical informatics, neurobiology, and genetic epidemiology, reflecting an interdisciplinary research orientation and collaboration. [1]

Research Contributions

Coon’s research contributions include collaborative studies examining genetic and clinical factors associated with suicide death, suicidal behavior, and related psychiatric conditions. Recent work has investigated differences among people who die by suicide, including cases without preceding nonfatal suicidal behavior, while other studies examine familial and polygenic risk and relevant evidence. [1] [2]

Publications

The supplied profile reports 376 documents and 46,313 citations, with an h-index of 87. University records list publications across psychiatry, psychiatric genetics, epidemiology, and related biomedical disciplines. Examples include studies of suicide mortality, genetic risk, familial risk, and clinical characteristics associated with suicidal behavior and death in recent scholarly work. [1]

Research Impact

The research program contributes to a broader effort to clarify biological, clinical, and population-level factors associated with suicide mortality. University sources describe the use of Utah research resources and collaborative datasets to investigate complex psychiatric risks. Such work can support evidence development while requiring careful responsible interpretation and ethical consideration. [1]

Award Suitability

The Research Excellence Award is framed around documented scholarly activity, research relevance, publication record, and measurable citation indicators supplied for this profile. Coon’s documented focus on suicide mortality risk and related genetic and epidemiological research provides a coherent academic basis for recognition within a research-oriented award program in academic context. [1]

Conclusion

Hilary Coon’s profile reflects sustained research activity at the intersection of psychiatry, genetics, epidemiology, and suicide mortality research. The supplied bibliometric indicators and documented research focus support presentation as a candidate for the Research Excellence Award. Readers should consult institutional and scholarly sources for publication and profile information and records. [1] [2]

References

  1. ORCID. (n.d.). Hilary Coon, ORCID iD 0000-0003-1675-5945. ORCID.
    https://orcid.org/0000-0002-8877-5446
  2. Coon, H., Shabalin, A. A., DiBlasi, E., et al. (2025). Understanding heterogeneity in suicidal thoughts and behaviours and the implications for genetic studies – a commentary on Lannoy et al. (2022).
    https://doi.org/10.1111/jcpp.13778
  3. International Invention Awards. (2026.). Official Award Information.
    https://inventionawards.org/

 

Leticia Szadai | Medicine and Dentistry | Best Researcher Award

Published on by Invention Awards

Best Researcher Award

Leticia Szadai
Lund University, Sweden

Leticia Szadai
Affiliation Lund University
Country Sweden
Google Scholar ID CNcrXOIAAAAJ
Documents 27
Citations 175
h-index 7
Subject Area Medicine and Dentistry
Event International Invention Awards

The Best Researcher Award recognizes researchers whose scholarly activities have contributed to the advancement of knowledge and innovation within their respective disciplines. Leticia Szadai of Lund University has developed a research profile centered on melanoma biology, proteomics, biomarker discovery, and translational cancer research. Her work integrates advanced molecular analysis with clinical applications, supporting improved understanding of melanoma progression, recurrence mechanisms, and therapeutic opportunities. Through collaborative research efforts, she has contributed to the generation of valuable datasets and analytical frameworks relevant to modern oncology research.[1]

Abstract

This article summarizes the academic achievements and research contributions of Leticia Szadai. Her work primarily focuses on melanoma proteomics, molecular pathology, biomarker identification, and translational oncology. Through participation in multidisciplinary investigations, she has contributed to the development of proteomic resources and analytical methods that support precision medicine approaches in cancer research.[2]

Keywords

Melanoma, Proteomics, Molecular Pathology, Biomarkers, Translational Medicine, Cancer Research, Precision Oncology, Tumor Biology.

Introduction

Advances in cancer research increasingly depend on interdisciplinary methodologies that connect molecular science with clinical practice. Leticia Szadai has contributed to this field through studies examining melanoma biology and the molecular factors associated with disease progression and recurrence. Her research reflects contemporary efforts to improve diagnostic and prognostic strategies through large-scale proteomic investigation.[3]

Research Profile

As a researcher affiliated with Lund University, Leticia Szadai has participated in projects involving molecular oncology, clinical proteomics, and translational medicine. Her publication record demonstrates engagement with collaborative international research initiatives focused on melanoma tissue analysis, mitochondrial regulation, immune response mechanisms, and biomarker discovery. These efforts contribute to the broader objective of enhancing evidence-based cancer management.[4]

Research Contributions

  • Contributed to studies establishing comprehensive melanoma proteome atlases.
  • Investigated molecular pathology and protein expression patterns in melanoma.
  • Explored mitochondrial dysfunction and immune response dysregulation associated with melanoma recurrence.
  • Participated in biomarker discovery using archived tumor samples and advanced proteomic technologies.
  • Supported research into kinase signaling pathways and translational applications in oncology.

Publications

  • The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome (2021).
  • The Human Melanoma Proteome Atlas—Defining the Molecular Pathology (2021).
  • Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence (2023).
  • Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out (2021).
  • A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma (2021).

Research Impact

The available citation metrics indicate that Leticia Szadai’s research outputs have attracted scholarly attention within oncology and translational medicine communities. Her involvement in high-impact collaborative studies has supported the development of proteomic resources that facilitate future investigations into melanoma progression, biomarker validation, and personalized therapeutic strategies. These contributions demonstrate measurable academic influence and continuing relevance to cancer research.[5]

Award Suitability

Leticia Szadai’s research portfolio aligns with the objectives of the International Invention Awards and the Best Researcher Award category. Her scholarly contributions reflect innovation in proteomic methodology, translational cancer research, and biomarker development. The combination of publication activity, collaborative leadership, and clinically relevant outcomes supports recognition for contributions to medicine and dentistry-related scientific advancement.[6]

Conclusion

Leticia Szadai has established a research profile characterized by rigorous investigation of melanoma biology and proteomics. Her contributions to translational oncology, biomarker discovery, and molecular pathology have supported scientific understanding of cancer mechanisms and potential clinical applications. These achievements provide a strong foundation for academic recognition through the Best Researcher Award.

References

  1. Elsevier. (n.d.). Google Scholar author details: Leticia Szadai
    https://scholar.google.com/citations?hl=hu&user=CNcrXOIAAAAJ
  2. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Complementing the Melanoma Transcriptome. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.451
  3. Betancourt LH et al. (2021). The Human Melanoma Proteome Atlas—Defining the Molecular Pathology. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.473
  4. Szadai L et al. (2023). Mitochondrial and Immune Response Dysregulation in Melanoma Recurrence. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.1495
  5. Szadai L et al. (2021). Deep Proteomic Analysis on Biobanked Paraffin-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers.
    https://doi.org/10.3390/cancers13236105
  6. Velasquez E et al. (2021). A Biobanking Turning-Point in the Use of Formalin-Fixed, Paraffin Tumor Blocks to Unveil Kinase Signaling in Melanoma. Clinical and Translational Medicine.
    https://doi.org/10.1002/ctm2.466

A. Marcell Szasz | Medicine and Dentistry | Excellence in Research Award

Published on by Invention Awards

Excellence in Research Award

A. Marcell Szasz
Semmelweis University, Hungary

A. Marcell Szasz
Affiliation Semmelweis University
Country Hungary
Scopus ID 24723204500
Documents 147
Citations 4,107
h-index 29
Subject Area Medicine and Dentistry
Event International Invention Awards
Google Scholar ID eeJzLNQAAAAJ

The Excellence in Research Award recognizes researchers whose scholarly activities demonstrate sustained contributions to scientific advancement, interdisciplinary collaboration, and measurable research impact. A. Marcell Szasz of Semmelweis University has developed a notable academic profile in medicine and cancer research through influential publications, biomarker studies, translational oncology investigations, and evidence-based clinical analyses.[1] His publication record and citation performance indicate significant engagement within the international scientific community.[2]

Abstract

A. Marcell Szasz has contributed to the fields of oncology, molecular medicine, prognostic biomarker analysis, and cancer outcome prediction. His research portfolio encompasses gene-expression studies, clinical meta-analyses, cancer progression modeling, and translational medical investigations. Through collaborations with international research teams, his work has informed understanding of disease mechanisms and patient stratification approaches in modern oncology.[2]

Keywords

Oncology, Biomarkers, Precision Medicine, Cancer Research, Meta-analysis, Gene Expression, Translational Medicine, Clinical Research.

Introduction

Research excellence is frequently evaluated through scientific influence, publication quality, citation impact, and contribution to knowledge development. Within this context, A. Marcell Szasz has established a scholarly presence through studies addressing cancer biology, prognostic biomarkers, and therapeutic outcomes. His work contributes to evidence-based approaches used in clinical and translational medicine.[3]

Research Profile

The researcher maintains a substantial publication portfolio consisting of 147 indexed documents, more than 4,100 citations, and an h-index of 29. His academic activity is primarily associated with medicine, oncology, pathology, molecular diagnostics, and clinical outcome assessment. These metrics reflect both productivity and sustained visibility within international scientific literature.[1]

Research Contributions

  • Investigation of microRNA regulation and metastatic progression in breast cancer.
  • Development and validation of transcriptomic biomarkers associated with survival outcomes.
  • Comprehensive meta-analyses supporting clinical decision-making in oncology.
  • Studies examining genomic alterations and evolutionary pathways of metastatic disease.

Publications

Among his most cited publications are studies on miR-31 and breast cancer metastasis, transcriptomic biomarker validation in gastric cancer, urachal carcinoma meta-analysis, tamoxifen-response biomarkers, and phylogenetic analyses of metastatic progression.[4] These works have received substantial scholarly attention and have been referenced extensively in subsequent research.

Research Impact

The citation performance associated with A. Marcell Szasz demonstrates broad engagement from researchers across oncology, pathology, molecular biology, and clinical medicine. His publications have contributed to methodological refinement, biomarker validation, and evidence synthesis efforts that support future investigations and clinical translation.[5]

Award Suitability

The Excellence in Research Award emphasizes scientific rigor, research influence, and sustained scholarly contribution. Based on publication metrics, citation impact, interdisciplinary collaborations, and documented contributions to cancer research, A. Marcell Szasz demonstrates characteristics commonly associated with distinguished academic achievement and research leadership.[6]

Conclusion

A. Marcell Szasz has contributed meaningfully to contemporary oncology research through studies addressing biomarkers, disease progression, and clinical outcomes. His publication record, citation profile, and participation in influential collaborative projects provide a strong foundation for recognition within an academic award framework focused on research excellence.

References

  1. Elsevier. (n.d.). Scopus author details: A. Marcell Szasz, Author ID 24723204500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24723204500
  2. Valastyan S., Reinhardt F., et al. (2009). miR-31 inhibits breast cancer metastasis. Cell.
    DOI: https://doi.org/10.1016/j.cell.2009.03.047
  3. Szász A.M., Lánczky A., et al. (2016). Cross-validation of survival associated biomarkers in gastric cancer. Oncotarget.
    DOI: https://doi.org/10.18632/oncotarget.10337
  4. Brown D., Smeets D., Székely B., Szasz A.M., et al. (2017). Phylogenetic analysis of metastatic progression in breast cancer. Nature Communications.
    DOI: https://doi.org/10.1038/ncomms14944
  5. Mihály Z., Kormos M., Lánczky A., et al. (2013). Gene expression-based biomarkers predicting outcome after tamoxifen treatment.
    DOI: https://doi.org/10.1007/s10549-013-2619-y
  6. Szarvas T., Módos O., Niedworok C., et al. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma.
    DOI: https://doi.org/10.1016/j.urolonc.2016.04.012